Steroids therapy
Phase 3Small molecule
Steroids therapy is one of 14 small molecule programs targeting Vestibular schwannoma. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Vestibular Schwannoma
#DrugCompanyPhaseTrials
1Garamycin
SSchering-Plough
Approved
Nimotop
AAzurity Pharmaceuticals
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Bayer Aspirin
BayerPhase 2
Avastin
BBio-Thera Solutions
Phase 2
Inlyta
PPrism Pharmaceuticals
Phase 2
Tasigna
AAzurity Pharmaceuticals
Phase 2
Xalkori
PPrism Pharmaceuticals
Phase 2
RAD001
NovartisPhase 2
Tykerb
GSKPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Vestibular schwannoma1 trial
Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients
Not yet recruiting·—·Phase 3·NCT07116811·364 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Steroids therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBeijing Tiantan Hospital